ST. JOSEPH, Mich., March 31 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today that Craig Webb, Ph.D., director of the Program of Translational Medicine at Grand Rapids, Mich.-based Van Andel Institute, has joined the MetaMiner Oncology Partnership Program.
The goal of the program is to develop a proprietary oncology pathway analysis platform built by experts in the field. This includes developing a series of blueprint pathway maps for cancers, collecting public domain experimental data and normalizing, parsing and making it available for use, as well as developing cancer specific ontologies.
"We feel that it is important to support such an initiative. There is an increasing amount of information in the cancer literature but no one has brought it all together in a set of comprehensive pathway maps that can be further explored," said Webb "This initiative will allow researchers to have more of a global perspective and allows newcomers to the field to get up to speed quickly."
Van Andel Institute announced in February an alliance and affiliation agreement with the Phoenix-based Translational Genomics Research Institute (TGen), one of the preeminent translational research organizations in the biomedical industry.
"Craig does amazing work at VAI, working with late-stage cancer patients to give them hope, and we are pleased to have him on our team," said Julie Bryant, GeneGo's VP of Business Development. "We have a lot of experience in cancer and have received millions of dollars in grants to fund our pioneering research."
About GeneGo, Inc.
GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics &
|SOURCE GeneGo, Inc.|
Copyright©2009 PR Newswire.
All rights reserved